Kallikrein-related Peptidase 5 (KLK5) Expression and Distribution in Canine Cutaneous Squamous Cell Carcinoma

被引:7
|
作者
Ortloff, A. [1 ]
Bustamante, F. A. [2 ,3 ]
Molina, L. [4 ]
Ojeda, J. [5 ]
Figueroa, C. D. [2 ,3 ]
Ehrenfeld, P. [2 ,3 ]
机构
[1] Univ Catolica Temuco, Fac Recursos Nat, Dept Ciencias Vet & Salud Publ, Temuco, Chile
[2] Univ Austral Chile, Inst Anat Histol & Pathol, Lab Cellular Pathol, Valdivia, Chile
[3] Univ Austral Chile, Ctr Interdisciplinary Studies Nervous Syst CISNe, Valdivia, Chile
[4] Univ San Sebastian, Fac Med & Ciencia, Lago Panguipulli 1390, Puerto Montt, Chile
[5] Univ Austral Chile, Hosp Vet, Valdivia, Chile
关键词
cutaneous squamous cell carcinoma; dog; epithelial-mesenchymal transition; kallikrein-related peptidase 5; HUMAN TISSUE KALLIKREINS; E-CADHERIN; VIMENTIN; PROSTATE; FAMILY;
D O I
10.1016/j.jcpa.2019.11.009
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Cutaneous squamous cell carcinoma (cSCC) is one of the most common types of malignant skin cancer in dogs, representing 3.9-10.4% of all canine skin tumours. Although the metastatic potential of cSCC is debated, it appears to mimic that observed in man. In man, predictive histopathological features for metastasis include tumour depth, lesions >5-6 mm in depth, and invasion of muscle, cartilage or bone. In dogs, some reports have focused on the clinical features and long-term progression of cSCC, but a gold standard treatment has not yet been developed. We explored the protein expression of kallikrein-related peptidase 5 (KLK5), an important modulator of skin homeostasis, in normal canine skin and in examples of cSCC. KLK5 was highly expressed in the upper stratum granulosum, stratum corneum, hair follicles and sweat glands, skin sites where human KLK5 has been shown to be involved in physiological processes including keratinocyte desquamation, antimicrobial defence, lipid permeability and pigmentation. In cSCC, tumour cells at the deep margin, as well as those in the centre of keratin pearls, displayed cytoplasmic expression of KLK5. Some of the KLK5 immunoreactive cells also expressed vimentin, suggesting that they may be undergoing epithelial-mesenchymal transition and therefore have a more invasive behaviour than those expressing only KLK5. KLK5 may be a novel molecular biomarker useful for predicting prognosis of cSSC in dogs. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页码:113 / 119
页数:7
相关论文
共 50 条
  • [1] Analysis and Clinical Evaluation of Kallikrein-Related Peptidase 5 (KLK5) in Colon Cancer
    Malachias, Apostolos
    Papachristopoulou, Georgia
    Kypraios, Dimitrios
    Bassioukas, Stefanos P.
    Nikaki, Maria
    Xinopoulos, Dimitrios
    Talieri, Maroulio
    GASTROENTEROLOGY, 2015, 148 (04) : S372 - S372
  • [2] Analysis of kallikrein-related peptidase 5 (KLK5) degradome in human keratinocyte secretome
    Di Paolo, Caitlin
    Diamandis, Eleftherios P.
    Prassas, Ioannis
    CLINICAL BIOCHEMISTRY, 2020, 86 : 82 - 82
  • [3] Uncovering the clinical impact of kallikrein-related peptidase 5 (KLK5) mRNA expression in the colorectal adenoma-carcinoma sequence
    Papachristopoulou, Georgia
    Malachias, Apostolos
    Devetzi, Marina
    Kamouza, Evdoxia
    Scorilas, Andreas
    Xynopoulos, Dimitris
    Talieri, Maroulio
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2019, 57 (08) : 1251 - 1260
  • [4] Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival
    Dorn, J.
    Magdolen, V.
    Gkazepis, A.
    Gerte, T.
    Harlozinska, A.
    Sedlaczek, P.
    Diamandis, E. P.
    Schuster, T.
    Harbeck, N.
    Kiechle, M.
    Schmitt, M.
    ANNALS OF ONCOLOGY, 2011, 22 (08) : 1783 - 1790
  • [5] Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival
    Dorn, J.
    Schuster, T.
    Gkazepis, A.
    Kiechle, M.
    Diamandis, E. P.
    Harlozinska, A.
    Magdolen, V.
    Schmitt, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: A biomarker for the differential diagnosis of breast lesions
    Avgeris M.
    Papachristopoulou G.
    Polychronis A.
    Scorilas A.
    Clinical Proteomics, 2011, 8 (1)
  • [7] Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors
    de Veer, Simon J.
    Swedberg, Joakim E.
    Brattsand, Maria
    Clements, Judith A.
    Harris, Jonathan M.
    BIOLOGICAL CHEMISTRY, 2016, 397 (12) : 1237 - 1249
  • [8] Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome
    Dorn, Julia
    Yassouridis, Alexandra
    Walch, Axel
    Diamandis, Eleftherios P.
    Schmitt, Manfred
    Kiechle, Marion
    Wang, Ping
    Drecoll, Enken
    Schmalfeldt, Barbara
    Loessner, Daniela
    Kotzsch, Matthias
    Magdolen, Viktor
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (01): : 61 - 70
  • [9] Kallikrein-related peptidase 13 expression and clinicopathological features in lung squamous cell carcinoma
    Sumiya, Ryusuke
    Yamada, Kazuhiko
    Hagiwara, Teruki
    Nagasaka, Satoshi
    Miyazaki, Hideki
    Igari, Toru
    Kawamura, Yuki I.
    MOLECULAR AND CLINICAL ONCOLOGY, 2023, 19 (02)
  • [10] Evaluation of Kallikrein-related Peptidase 5 Expression and its Significance for Breast Cancer Patients: Association with Kallikrein-related Peptidase 7 Expression
    Talieri, Maroulio
    Devetzi, Marina
    Scorilas, Andreas
    Prezas, Panagiotis
    Ardavanis, Alexandros
    Apostolaki, Aikaterini
    Karameris, Andreas
    ANTICANCER RESEARCH, 2011, 31 (09) : 3093 - 3100